Code usapeptidevendors: 25% off everything at · Purgo Labs

Related brand · disclosed
USA Peptide VendorsIndependent vendor reviews
Purgo Labsusapeptidevendors

Try

Skin & melanocortin research peptides

PT-141 (Bremelanotide) research dossier

Cyclic melanocortin receptor agonist; Melanotan II with a free-acid C-terminus. Bremelanotide acts mainly at central MC4R and was approved for hypoactive sexual desire disorder after two phase 3 trials.

Skin & MelanocortinCAS 189691-06-3BremelanotideUpdated 2026-11-09
Original illustration for PT-141 (Bremelanotide) research notes: abstract molecular artwork in orange and teal
Original illustration by USA Peptide Vendors; artistic, not a structural model.

At a glance

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.

CAS number
189691-06-3
Molecular formula
C50H68N14O10
Molecular weight
1025.16 g/mol
PubChem CID
9941379

Purgo's product data lists CAS 32780-32-8; the CAS above is PubChem's.

Verified 2026-11-09 against KEGG DRUG D06569 and PubChem CID 9941379. Values we couldn't verify are left out.

What the literature covers

Bremelanotide acts mainly at central MC4R and was approved for hypoactive sexual desire disorder after two phase 3 trials.

37 of 112 directory vendors list PT-141; 19 name their testing lab.

Proposed PT-141 signaling

Evidence level: Clinical: phase 2 and phase 3 trials. All mechanism maps

PT-141 mechanism diagramCentral melanocortin (MC4R) agonism and sexual response. Targets: MC4R. Site of action: Central melanocortin pathways. Effects reported: Erectile response, Sexual desire ↑.PT-141 mechanism mapCentral melanocortin (MC4R) agonism and sexual responsePT-141bremelanotideMC4Ralso MC3R [1]Central melanocortin pathways[1]Erectile responsemen, phase 2 [2]Sexual desire ↑women, phase 3 [3]Evidence: Clinical: phase 2 and phase 3 trials. Numbers in brackets refer to the citedsources.usapeptidevendors.com · Research Use OnlyRECEPTORSITE OF ACTIONEFFECTS REPORTED
Approved as a pharmaceutical injection; research-catalog sprays are a different formulation. Open SVG
  1. Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  2. Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16:51-9.
  3. Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134:899-908.

Before you order

  • Purgo sells it as “PT-141”. Make sure the COA names the analyte, not just the store label.
  • Match the CAS number on the certificate to 189691-06-3.
  • 37 of the 112 vendors in our directory list PT-141; 19 of those name the lab that tests it.

FAQ

What is PT-141 (Bremelanotide)?

Cyclic melanocortin receptor agonist; Melanotan II with a free-acid C-terminus. Bremelanotide acts mainly at central MC4R and was approved for hypoactive sexual desire disorder after two phase 3 trials.

What are PT-141 (Bremelanotide)'s CAS number and molecular weight?

CAS 189691-06-3, formula C50H68N14O10, 1025.16 g/mol, per KEGG DRUG D06569 and PubChem CID 9941379. Purgo's product data lists CAS 32780-32-8; the CAS above is PubChem's.

Where can US labs buy PT-141 (Bremelanotide)?

Purgo Labs stocks it as “PT-141”; code usapeptidevendors takes 25% off at checkout. This page also lists the best-documented second vendor from our 112-vendor directory.

Is research-grade PT-141 (Bremelanotide) for human use?

No. Vendor material is sold for Research Use Only, not for human or veterinary use.